Identification
Instrument name
KIADIS
Symbol
KDS
ISIN code
NL0011323407
Exchange / Market
Euronext
Trading location
Amsterdam
Brussels
Products family
Stocks
Capitalization compartment
Compartment C
ICB
Biotechnology
Website address
Operation
IPO date
Issue type
Initial Public offering
Cat├ęgorie
IPO
Price range
EUR 11.00 - EUR 13.75

Company profile

Kiadis Pharma N.V., is a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices in the US and across Europe, Kiadis Pharma N.V. is leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Source: Cofisem - Last Update: 13 Feb 2020
Key Executives
Chief Executive Officer Arthur Lahr
Company Secretary James Joy
Chief Financial Officer Scott Holmes
VP, Investor Relations Amy Sullivan
Human Resources Director Mark Schaefer
Source: Cofisem - Last Update: 25 Jul 2019
Key figures
Millenium 2018 2017 2016 2015 2014
Net sales
Income from ordinary activities
Operating income -25,201 -16,120 -11,408 -16,007 -6,168
Cost (net) of financial indebtedness -4,302 -2,285 -1,558 -1,344 -1,045
Equity-accounted companies' contribution to results
Net profit from discontinued activities
Net income -29,801 -17,038 -14,794 -16,457 -7,813
Net income (Group share) -29,801 -17,038 -14,794 -16,457 -7,813
Fiscal year end 12.18 12.17 12.16 12.15 12.14
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards
Source: Cofisem - Last Update: 13 Feb 2020
Shareholder information
FIL 2.96 %
Source: Cofisem - Last Update: 30 May 2019